Information Provided By:
Fly News Breaks for November 21, 2019
Nov 21, 2019 | 09:40 EDT
Roth Capital analyst Zegbeh Jallah said she believes Harpoon Therapeutics' (HARP) expanded agreement with AbbVie (ABBV) is both a strong indication of AbbVie's confidence in the platform as well as "a superb strategic move" for Harpoon. The new deal expands the existing October 2017 discovery and collaboration agreement while also establishing a new licensing and option agreement with Harpoon for HPN217, all while providing "an excellent source of additional cash" for Harpoon, Jallah tells investors. She has a Buy rating on Harpoon shares.
News For HARP;ABBV From the Last 2 Days
Dec 6, 2021 | 09:40 EST
Unusual total active option classes on open include: WeWork (WE), SPDR S&P Regional Banking (KRE), Ardelyx (ARDX), DocuSign (DOCU), Pinduoduo (PDD), Rocket Lab USA (RKLB), Global X Uranium (URA), Norwegian Cruise Line (NCLH), Chewy (CHWY), and AbbVie (ABBV).
Dec 6, 2021 | 08:32 EST
AbbVie announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week 12. The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60% having previously failed two or more biologics. U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. "The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino, M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."